10月23日，阳光诺和盘中下跌2.06%，截至09:48，报59.01元/股，成交2707.82万元，换手率0.40%，总 市值66.09亿元。 资金流向方面，主力资金净流出323.27万元，特大单买入0.00元，占比0.00%，卖出101.74万元，占比 3.76%；大单买入598.57万元，占比22.11%，卖出820.11万元，占比30.29%。 阳光诺和今年以来股价涨57.19%，近5个交易日跌5.14%，近20日跌24.83%，近60日涨7.15%。 责任编辑：小浪快报 资料显示，北京阳光诺和药物研究股份有限公司位于北京市昌平区科技园区双营西路79号院7号楼，成 立日期2009年3月9日，上市日期2021年6月21日，公司主营业务涉及仿制药开发、一致性评价及创新药 开发等方面的综合研发服务,服务内容主要包括药学研究、临床试验和生物分析。主营业务收入构成 为：CRO业务99.91%，其他(补充)0.09%。 分红方面，阳光诺和A股上市后累计派现1.05亿元。近三年，累计派现8429.23万元。 机构持仓方面，截止2025年6月30日，阳光诺和十大流通股东中，融通健康产业灵活配置混合A/B （00072 ...

Core Viewpoint - Sunshine Nuohua's stock price has declined for five consecutive days, with a total drop of 11.3% during this period, indicating potential concerns among investors regarding the company's performance and market conditions [1]. Company Overview - Sunshine Nuohua Pharmaceutical Research Co., Ltd. is located in Changping District, Beijing, and was established on March 9, 2009. The company went public on June 21, 2021. Its main business involves the development of generic drugs, consistency evaluation, and innovative drug development, primarily focusing on pharmaceutical research, clinical trials, and bioanalysis [1]. - The revenue composition of the company is heavily weighted towards CRO (Contract Research Organization) services, accounting for 99.91% of total revenue, with other services contributing only 0.09% [1]. Shareholder Insights - Anxin Fund's Anxin Medical Health Stock A (010709) is among the top ten circulating shareholders of Sunshine Nuohua. In the second quarter, it reduced its holdings by 266,500 shares, retaining 1.442 million shares, which represents 1.29% of the circulating shares. The estimated floating loss today is approximately 1.5285 million yuan, with a total floating loss of 10.8872 million yuan over the five-day decline [2]. - Anxin Medical Health Stock A was established on January 12, 2021, with a current scale of 442 million yuan. Year-to-date returns stand at 63.14%, ranking 222 out of 4220 in its category, while the one-year return is 53.22%, ranking 797 out of 3857 [2]. Fund Positioning - Anxin Medical Health Stock A has Sunshine Nuohua as its fourth-largest holding, with 1.442 million shares representing 7.61% of the fund's net value. The estimated floating loss for today is around 1.5285 million yuan, with a cumulative floating loss of 10.8872 million yuan during the recent five-day decline [3].

Core Viewpoint - On October 9, Sunshine Nuohuo experienced a decline of 2.85% with a trading volume of 240 million yuan, indicating a potential concern regarding its stock performance [1]. Financing Summary - On October 9, Sunshine Nuohuo had a financing buy-in amount of 45.86 million yuan, with a net financing buy of 109,600 yuan, while the total financing and securities balance reached 518 million yuan, accounting for 7.20% of its market capitalization [1]. - The financing balance of 518 million yuan is above the 70th percentile level over the past year, indicating a relatively high level of financing activity [1]. Securities Lending Summary - On October 9, there were no shares repaid or sold in securities lending, with a total lending balance of 0 shares, which is above the 80th percentile level over the past year, suggesting a high level of lending activity [1]. Company Overview - Sunshine Nuohuo, established on March 9, 2009, and listed on June 21, 2021, is located in Beijing and specializes in generic drug development, consistency evaluation, and innovative drug development, with 99.91% of its revenue coming from CRO services [1]. - As of June 30, the number of shareholders increased by 18.76% to 8,621, while the average circulating shares per person decreased by 15.80% to 12,991 shares [2]. Financial Performance - For the first half of 2025, Sunshine Nuohuo reported a revenue of 590 million yuan, representing a year-on-year growth of 4.87%, while the net profit attributable to shareholders decreased by 12.61% to 130 million yuan [2]. Dividend Information - Since its A-share listing, Sunshine Nuohuo has distributed a total of 105 million yuan in dividends, with 84.29 million yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, the fourth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B, holding 2.55 million shares, a decrease of 58,600 shares from the previous period [3].